Greeley said ‘Go West’ — I decided to ‘Go North’

It is often thought that “the grass is always greener on the other side of the (pick one: fence, hill, road, wall, or whatever).” It’s a thought so much stated that the time-worn bromide is among “the 50 most important proverbs” as listed online by phrasemix.com.

After completing one year of in-center dialysis at the end of this past January, I found myself contemplating whether a fresh medical evaluation might be in the best interest of assessing my mortality. In other words, what are the possibilities looking ahead? And what is available ongoing that I as an end stage renal disease patient can control?

Being a retired journalist, it is appropriate that a phrase often credited to the American author and newspaper editor Horace Greeley crossed my mind: “Go West, young man, and grow up with the country.” Of course, I am no longer anywhere near being a young man, and I have no intention of subscribing to that popular concept of the mid-1800s known as the Manifest Destiny, a widely held belief in the United States that its settlers were destined to expand across North America.

What has become prevalent nowadays, though, is what many patients face in dealing with a current chronic disease, and perhaps with an impending surgical procedure. Often, after they get the original prognosis, they seek a second opinion. Or maybe a third. And often what falls on patients’ ears at each stop are the same old lines of embarkment. This is the treatment you need; this is the protocol for what needs to be done. And in many cases, it needs to be done right away.

For those who have reached the final stage of kidney disease, the options for treatment in the Western civilization are pretty much set in stone – go on dialysis for the rest of your life, … or receive a kidney transplant. Neither are all that inviting, although those are the methods available in this country for prolonging your existence.

Also, among my several thoughts were those gleaned from Indiana author Mark Montieth, a familiar sports writer and television/radio personality. I have known of Montieth for some years but only met him face-to-face once. A few years back, Mark had the gumption to defy traditional Western civilization treatment in coping with squamous cell carcinoma, a cancer which began with a tumor on his tonsils and spread to his lymph nodes. According to his story – which is documented on his markmontieth.com website – the cancer was the result of a virus, HPV 16.

Montieth’s parents and older brother have owned a natural food store, Georgetown Market, on Indy’s northwest side since 1973. What Mark had heard from one doctor after another was needed in treating his disease didn’t set quite right with his upbringing.

In one portion of his online account, Montieth writes: “I know of and believe in the world of natural ‘medicine,’ and have always believed instinctively the body usually can heal itself with the proper nutrients. I also believe traditional medicine is mostly a corporate, profit-motivated enterprise, filled with some great minds and good-hearted people but also no shortage of brainwashed money-grubbers who care more about their bank accounts than their patients. It requires massive overhead to keep all those high-tech cancer centers operating, and the only way for them to do it is with the income from chemo and radiation treatments. A ‘cure’ might shut them all down and put thousands of people out of work.”

What Montieth ultimately did was sidestep traditional medicine, deciding to follow as natural a path as possible. That included some local holistic treatment sessions and consultations from outside the United States (and outside Indiana). In the long run, this stubborn and determined warrior beat his cancer, and offers a compelling account of his journey.

I certainly don’t have the background in natural healing that Montieth has. However, I did encounter – through research while writing a recent book titled Dialing in on DI-AL-Y-SIS – an interesting Australian fellow by the name of Duncan Capicchiano. For more than a dozen years, this certified naturopath has promoted a program known as The Kidney Disease Solution. The program, according to his website beatkidneydisease.com, is a complete and holistic approach to regaining kidney function and for living a normal healthy life.

I literally bought into his program and have been using many of the specifically created to fit the 80/20 ratio of alkalizing/acidifying ingredients by volume required during the restorative phase of The Kidney Disease Solution treatment. I am convinced the material in his 130-page cookbook and kitchen companion guide was instrumental in helping me attain consistent monthly lab results and satisfactory daily weight readings.    

After weighing in on a mixture of the English proverb, the Horace Greeley suggestion, and the Mark Montieth testimonial on beating cancer, my thoughts finally crystallized into a decision on what to do about obtaining a fresh evaluation on my mortality. While not necessarily expecting greener pastures, nor hankering to “Go West,” I did decide to transition to a different treatment facility on the south side of Indianapolis.That entailed being accepted by a newly certified Fresenius Dialysis Care operation and “Going North” about a mile to near the corner of Southport Road and South Madison Avenue. My first session was on Valentine’s Day (February 14), and my new starting time aligns with the roosters at 6 o’clock in the morning on Mondays, Wednesdays, and Fridays.

I do acknowledge being somewhat comfortable in recognizing that the past half dozen months or so have been rather consistent when assessing lab work. And I have been “feeling fine,” too. However, my sales background tells me that status quo is not good enough. A successful sales organization relishes a gain in production; otherwise, there is the perspective of falling behind.

So far, on perhaps the greener side at the Fresenius center are the individual patient TV sets that include some sports channels. And hopefully looming ahead is a fresh evaluation of my current and likely future on or off dialysis.  As legendary baseball pitcher Satchel Paige once said: “Don’t look back. Something may be gaining on you.”

Maintain hope in research while coping with dialysis

While coping with the day-to-day life of being on dialysis, I keep my chin up by following the progression of Kidney Project, a research effort that lends hope to the thousands upon thousands of us tethered with end stage renal disease.

Just how much hope that someday many of us may be able to rid ourselves of dialysis altogether is yet to be determined. Any hope at all for many of us, though, makes treatment days at a mundane dialysis center that more tolerable.

For now, the measure of this hope is in the hands of those who are working in collaboration to create an implantable bioartificial kidney that likely will alter the lives of ESRD patients. When the day comes that turns hope into reality will no doubt vastly impact the renal disease industry.

In my recent book – Dialing in on DI-AL-Y-SIS – I devoted a chapter toward several areas beyond current traditional treatment options that might provide needed hope for renal disease patients. Kidney Project was one research effort that offered some in-depth information.

Until that time comes when an implantable artificial kidney truly becomes a reality, there is a place to go on the internet for timely updates – www.facebook.com/ArtificialKidney. A most recent posting (January 30) reports on the status of Kidney Project’s preclinical testing. It states:

“The Kidney Project is (in the midst of) transitioning out of preclinical testing for the Hemofilter, while preclinical testing for the Bioreactor is underway. Results from preclinical testing of the Hemofilter are encouraging. We have successfully implanted the Hemofilter component into large animal models for up to 1 month. The animals responded well, without serious complications. We have collected enough preclinical data to apply for our first clinical trial and are waiting for approval for our first application.”

A post a week earlier addressed how the bioartificial kidney device works, and how big the device really is.

“The bioartificial kidney, the size of a coffee cup, consists of two modules that work together to get rid of wastes. First, a hemofilter module processes incoming blood to create a watery ultrafiltrate that contains dissolved toxins as well as sugars and salts. Second, a bioreactor of kidney cells processes the ultrafiltrate and sends the sugars and salts back into the blood. In the process, water is also reabsorbed back into the body, concentrating the ultrafiltrate into “urine,” which will be directed to the bladder for excretion.”

In May of 2017, the project’s two front-line doctors – Dr. Shuvo Roy of University at California San Francisco and William Fissell at Vanderbilt University – were quoted on how the success of Kidney Project can carry such an impact.

Said Dr. Roy: “Our goal is to eliminate the burdens of dialysis by providing an implantable device that provides both the clearance and biological functions of a kidney.”

Stated Dr. Fissell: “The project is about creating a permanent solution to the scarcity problem in organ transplantation. We are increasing the options for people with chronic kidney disease who would otherwise be forced into dialysis.”

Whenever the hope of Kidney Project becomes a reality, the materialization of such a breakthrough has been promised help by the U.S. Food & Drug Administration. The FDA has selected Kidney Project to a new regulatory approval program called Expedited Access Pathway. EAP is intended to bring breakthrough medical device technologies to patients faster and more efficiently.

From the viewpoint of we treatment patients, Kidney Project success can come as soon as tomorrow.

End Nearing for 1st Year on Dialysis

This very cold month of January (2018) will conclude my first year of being on dialysis.

I am not looking at month’s end as a time for celebration; there are no plans for a party in behalf of surviving one year in partnering with Count Dracula, the name I have given my dialysis machine. Rather, I consider the month’s end as more of one as recognition – a time to acknowledge that my life likely has been prolonged. And done so by a process that three times a week circulates the 10 or 11 pints of my blood, while methodically filtering it each treatment day (about three complete cycles) in removing any excess fluid and cleansing the bloodstream of any bad-boy toxins.

As a result, I generally feel pretty good going into and coming out of dialysis, along with the time in between. Maybe that is reason for celebration.

What I do savor about the past 12 months are the conversations with fellow end stage renal disease patients, and several of the people who I have become acquainted with in doing research for my new book titled Dialing in on DI-AL-Y-SIS and some others who fall into the category of book writers. Among the latter are World Series baseball champion Ed Hearn, University of Cincinnati professor emerita Angelene J. Hall, and noted kidney disease advocate Jim Dineen.

** I have known of Ed Hearn since he was a member of the 1986 World Series champion New York Mets, and soon after involved in a trade that took him to the Kansas City Royals, my favorite team ever since the team’s inception in 1969.

Hearn, whose lengthy Minor League run (eight seasons) but very brief Major League stint was shortened by injuries, was featured in a chapter of my book. Following his baseball career, he endured medical struggles with several very serious diseases – chronic renal disease that forced him through years on dialysis followed by three kidney transplants, a life-threatening sleep disorder, and battles with carcinoma, a type of cancer that requires radiation and a multitude of prescribed pills.

The Florida-born Hearn in 1996 wrote a book titled Conquering Life’s Curves that I discovered while researching my book. I ordered a copy of Ed’s hardcover offering and found it to be an uplifting find. It took me only one overnight read to finish it, and soon thereafter I enjoyed a memorable telephone chat with him, the first kidney transplant recipient I had ever indulged in conversation.

In the past couple of decades, Hearn has become one of the top 10 inspirational speakers in the country.

** I came to know of Angelene J. Hall just this past holiday season when my second-oldest daughter, Erin Gilmer, provided me with a book receipt in a festive bag beneath our modest window-box tree. The thoughtful reading titled Duck Summer was en route, arriving a few moons after Christmas Day. Angelene’s interesting book chronicles her six-year odyssey on dialysis that preceded her eventual kidney transplant in 2004.

After reading Hall’s book, I was able to connect with her by telephone. She still resides in Cincinnati, and Summer Duck, her most recent literary writing, represents her efforts in using her experiences with ESRD to educate the public about renal decline and ultimate failure, dialysis treatment, and the urgency of organ donation.

** Even more recently, I have had an occasion to hook up through Facebook and by email with dialysis patient/kidney transplant recipient Jim Dineen. The West Chester (Ohio) former steel industry manager penned a poem titled Those Who Go, Those Who Stay that appears in my book as a very appropriate presentation.

Jim wrote the poem in 1990, when someone asked him about his experiences during the Vietnam War. His daughter, Shari, then painted a picture for him using his poem as her inspiration. The picture has the same title and depicts a Vietnam veteran kneeling at “The Wall” memorial in Washington, D.C.

Dineen was diagnosed with kidney failure in 1998. After three years on dialysis, he received a kidney in November of 2003 from Joyce, his wife of more than 40 years. In June of 2004, their story was featured in Readers Digest, focusing on how kidney disease dramatically affected their family and brought them together.

In addition to his poetic prowess, Dineen has authored two books – one titled Life’s Just Not That Complicated and another titled Stand Up, SPEAK! He also since his transplant has dedicated hours upon hours of time and effort as a spokesman for kidney disease at various levels of advocacy.

Though Dineen’s poem originally was written with a specific subject in mind, the words, according to the author himself, “also ring true for everyone, and especially for those of us with kidney disease.”

Dineen’s poem – Those Who Go, Those Who Stay – appears in Dialing in on DI-AL-Y-SIS as follows:

Those Who Go, Those Who Stay

 By Jim Dineen (dialysis patient, transplant recipient)

 If time were a day, or a week, or a year,

and friends were the fluid that creates a tear;

Then life for me continues a dream ….

Bear with me a moment, here’s what I mean.

 

I’ve lost a few throughout my life,

Some ’cause natural, others ’cause strife;

And through it all some things remain …

Life’s really not cruel, it just has some pain.

 

 When we rise each morning, sun shining or not,

Don’t think of who’s gone, but think of who’s not;

And give them respect and warmth and love

to get through their day on the wings of a dove,

Or maybe an eagle, an osprey’s wing …

Give them something to make their hearts sing.

 

You see, our friends, through life’s perils and strains,

are always ours, regardless of pain;

Always seeing the good, forgetting the bad,

that each of us shows whether happy or sad;

Whether times are good or sometimes hard,

they’re there for us, they’ll deal the card

That’s best for us when we’re in need …

No questions asked, simply planting the seed.

 

The end of this piece is nowhere to be found,

’cause just like our lives, it flows ’round and ’round;

New friends will come, and old ones will go,

But the ones we know best continue to show

The need for our presence, the need for our trust …

Look around you, my friends, those folks are us.

Are we splitting hairs on ideal body weight?

A post shared by noted Facebook kidney disease advocate James Myers caught my attention regarding Ideal Body Weight. Many dialysis patients such as myself take a serious approach to keeping our scale weight into the close vicinity of our dry weight. I know that I do on a daily basis.

My actual height is 5-feet, 8 1/2-inches. My scale weight has fluctuated between 164 pounds to 168 pounds over the past seven to eight months, ever since I was placed on dialysis on February 1 (2017).

The Ideal Body Weight chart has me, a male, using a midway point between 5-foot 8 and 5-foot 9, which would set my Ideal Body Weight at 157 pounds or 71.2 kilos.
My dry weight has been established by my treatment clinic doctors and staff at 76.5.

On many treatment day weigh-ins the scale reflects figures below the dry weight level; therefore, on many occasions Count Dracula (the dialysis machine) has little or no excess fluid to draw on. That leaves my three and one-half hours of treatment relegated to only circulating my blood in removing those bad-boy toxins.

On several occasions, nurses and technicians have suggested lowering the dry weight level, which likely would call for more frequent drawing of excessive liquids. I balk at that notion. Why? I perceive myself as being too skinny as it is. With the exception of the first six weeks of dialysis, when my scale weight of more than 200 pounds was brought down to 163 pounds, I have come to dialysis feeling good, and I leave dialysis feeling good. My monthly lab work consistently falls within the parameters desired by my dietician and by the Kidney School’s charts that provide an understanding of lab results. Even my heart doctor has encouragingly cleared me to resume playing tennis, when and if we ever enjoy much better outdoor weather.

So far, even the doctors at Premier Dialysis where I receive treatments three days a week, the lowering of my dry weight has become a mute topic. Since my stamina remains constant, evidenced by my wife (Maureen, the chauffeur) and I on occasion leaving my treatment center for a restaurant meal, or to walk the aisles at a grocery store for a basket full of sustenance.

Hopefully, I will discover that my stubbornness over lowering my dry weight is just a matter of splitting hairs. Or maybe I just need to grow a couple of inches while maintaining my current weight fluctuation.

AUTHOR’S WEBSITE RECEIVES RECOGNITION

Notification was received early on Tuesday morning (January 2) that blogs written by Indianapolis (Indiana) author and renal disease patient Bernie Gilmer and his diodialysis.com website have received recognition by the international Feedspot organization.

The posts also have appeared on his personal Facebook page and his Dio Dialysis Co. dialysis Facebook page.

Founded by Anuj Agarwal, Feedspot’s most recent list published on feedspot.com/dialysis blogs/ places diodialysis.com/blog in the No. 13 ranking.

In an email which announced the recognition, Agarwal stated: “I personally give you a high-five and want to thank you for your contribution to this world. This is the most comprehensive list (of top dialysis blogs) on the internet and I’m honored to have you as part of this!”

According to a Feedspot news release, the list of Best Dialysis blogs is developed from reviewing thousands of top dialysis blogs in the organization’s index using search and social metrics. These blogs are ranked based on the following criteria.

  • Google reputation and Google search ranking.
  • Influence and popularity on Facebook, twitter and other social media sites.
  • Quality and consistency of posts.
  • Feedspot’s editorial team and expert review.

The top dialysis blogs for the first week of 2018 include:

  1. News Medical Life Sciences/Dialysis
  2. Reddit/Kidney failure
  3. kidneydialysisnews.blogspot.com
  4. 00kidney.blogspot.com
  5. patsdialysis.blogspot.com
  6. bigdandme.blog
  7. ajkdblog.org/tag/peritoneal-dialysis/
  8. hemowear.com/blog
  9. dialysisjobsweekly.com/blog
  10. jhdialysis.com
  11. dialysisadvocates.com/news
  12. johannamckinley.com/inadialysisdaizeblog/
  13. diodialysis.com/blog
  14. reliantrenalcare.com/blog
  15. miketolcher.com/blog
  16. curesnow.blogspot.com
  17. alysia.info/blog
  18. dialysis4career.com/blogs
  19. dialysistechniciansworldwide.blogspot.com
  20. dobsonondialysis.wordpress.com

The Feedspot’s listings are refreshed weekly.

 

THE NATURE OF THE BEAST

The past week has been an extremely sad one at the Premier Dialysis center for myself, other end stage renal disease patients and their families, and staff members. We lost two dear patients whose battles with kidney disease and associated ailments came to an end.

The past week, and perhaps on half a dozen other times since I went on dialysis on February 1 of this year, is a reminder that being on this treatment routine becomes a time when coping is most difficult. Dialysis is a treatment process that is designed to prolong lives of those who reach the end stage of renal disease. At some time during the treatment process – perhaps days, weeks, months or years along the way – the prolonging of life unfortunately must come to an end.

About three decades ago, I wrote a newspaper column titled THE NATURE OF THE BEAST handed down to me by my older brother. Somewhere within the writing of that column might be a message that can help those of us on ESRD who try to cope with everyday life. What I gather each time I re-read the column is that if I can learn everything possible about this beast we know as dialysis, then perhaps it will not devour our hopes and beliefs.

The column follows:

THE NATURE OF THE BEAST
By Bernie Gilmer Belvidere Daily Republican
Saturday, February 7, 1987

This handed-down story goes back many decades … back to when plantations flourished in the South. Owners of these large operations – throughout Georgia, Alabama and Mississippi, for example – took time almost daily to “sit a spell” on their front porches.

It was meditation time. Cogitation time. Time for reflection. Or whatever, perhaps a pitcher of fresh-squeezed lemonade. It was time to mentally cover the expanse of the plantation, to admire what one powerful individual – with a labor force of slaves – could accomplish by working the land properly and could acquire through shrewd exchange at the marketplace.

One particular plantation owner was accustomed to his daily “sit a spell” routine. He would pull up his basket-woven chair, prop his feet cross-legged on the railing in front of him – right next to one of the two-story white columns that majestically fronted his mansion – and lean back on the two rear chair legs.
Yes, it was meditation time. Cogitation time. Time for reflection, and perhaps some freshly-squeezed lemonade.

It was an era before Lincoln … before Selma … before Wallace … before Cumming. It was an era of peacefulness on the land. It was a time of prosperity for barons of the land.

This particular plantation owner had an unusual companion during his daily “sit a spell” sessions. Lying close-by, tongue wagging in the heat and with sweat running down beside restful eyes into a thick hairy growth that extended over slightly moistened lips was his pet – a fully matured lion.

Now, not many plantation owners in those days had pet lions (most had a few hounds and maybe some cats), but this unusual beast had been acquired during a trading session while it was still a cub. During its growing years, the lion became known throughout that part of the country, and you can bet your Confederate flag it soon became respected by any unsuspecting visitor, not to mention the slave contingency. In fact, many acquaintances recognized that the plantation owner and the lion had over the years become rather inseparable.

One day this particular plantation owner was “sitting a spell” next to one of the big white columns when his balance shifted backwards on the two rear chair legs. To keep from tumbling backwards, the plantation owner tried to catch his left foot on the closest of the two-story white columns. In so doing, the outside of his leg dragged across a protruding wooden nail, cutting the owner’s leg to the extent of drawing a trickle of blood.

The blood proceeded to drip rhythmically – splat … splat … splat – down onto the paw of the lion, which was resting in his customary spot on the porch beside the landowner. After a few drops had saturated the paw and splashed onto the floor, the lion began licking – first slowly, then a little more quickly. It was the lion’s first taste of human blood.

Without hesitation, the plantation owner regained his balance in the chair, eased himself up and crossed the porch to where he had propped his shotgun against a window facing. Slowly and sadly, he crossed back to where the lion was still licking his paw … and with one pull of the trigger he killed the lion.

The moral of the story: Understand the nature of the beast and it will not devour you.

Somehow, this story and its moral can be applied to many present-day situations. We need to recognize who and what we are dealing with in our daily situations. It might help in coping.

Meditate on it. Cogitate on it. Reflect on it.

Silicon Not Just for Computers: Can Make a Pretty Good Kidney, Too

NOTE: The following online article is written by Megan Molteni, a staff writer at WIRED, where she covers biology, health, technology and the environment. The update on Project Kidney was posted this past October on Wired.com.

Every week, two million people across the world will sit for hours, hooked up to a whirring, blinking, blood-cleaning dialysis machine. Their alternatives: Find a kidney transplant or die.

In the US, dialysis is a roughly 40-billion-dollar business keeping 468,000 people with end-stage renal disease alive. The process is far from perfect, but that hasn’t hindered the industry’s growth. That’s thanks to a federally mandated Medicare entitlement that guarantees any American who needs dialysis—regardless of age or financial status—can get it, and get it paid for.

The legally enshrined coverage of dialysis has doubtlessly saved thousands of lives since its enactment 45 years ago, but the procedure’s history of special treatment has also stymied innovation. Today, the US government spends about 50 times more on private dialysis companies than it does on kidney disease research to improve treatments and find new cures. In this funding atmosphere, scientists have made slow progress to come up with something better than the dialysis machine-filled storefronts and strip malls that provide a vital service to so many of the country’s sickest people.

We thought, if people are growing ears on the backs of mice, why can’t we grow a kidney?

Now, after more than 20 years of work, one team of doctors and researchers is close to offering patients an implantable artificial kidney, a bionic device that uses the same technology that makes the chips that power your laptop and smartphone. Stacks of carefully designed silicon nanopore filters combine with live kidney cells grown in a bioreactor. The bundle is enclosed in a body-friendly box and connected to a patient’s circulatory system and bladder—no external tubing required.

The device would do more than detach dialysis patients—who experience much higher rates of fatigue, chronic pain, and depression than the average American—from a grueling treatment schedule. It would also address a critical shortfall of organs for transplant that continues despite a recent uptick in donations. For every person who received a kidney last year, 5 more on the waiting list didn’t. And 4,000 of them died.

There are still plenty of regulatory hurdles ahead—human testing is scheduled to begin early next year1—but this bioartificial kidney is already bringing hope to patients desperate to unhook for good.

Kidneys are the body’s bookkeepers. They sort the good from the bad—a process crucial to maintaining a stable balance of bodily chemicals. But sometimes they stop working. Diabetes, high blood pressure, and some forms of cancers can all cause kidney damage and impair the organs’ ability to function. Which is why doctors have long been on the lookout for ways to mimic their operations outside the body.

The first successful attempt at a human artificial kidney was a feat of Rube Goldberg-ian ingenuity, necessitated in large part by wartime austerity measures. In the spring of 1940, a young Dutch doctor named Willem Kolff decamped from his university post to wait out the Nazi occupation of the Netherlands in a rural hospital on the IJssel river. There he constructed an unwieldy contraption for treating people dying from kidney failure using some 50 yards of sausage casing, a rotating wooden drum, and a bath of saltwater. The semi-permeable casing filtered out small molecules of toxic kidney waste while keeping larger blood cells and other molecules intact. Kolff’s apparatus enabled him to draw blood from his patients, push it through the 150 feet of submerged casings, and return it to them cleansed of deadly impurities.

In some ways, dialysis has advanced quite a bit since 1943. (Vaarwel, sausage casing, hello mass-produced cellulose tubing.) But its basic function has remained unchanged for more than 70 years.

Not because there aren’t plenty of things to improve on. Design and manufacturing flaws make dialysis much less efficient than a real kidney at taking bad stuff out of the body and keeping the good stuff in. Other biological functions it can’t duplicate at all. But any efforts to substantially upgrade (or, heaven forbid, supplant) the technology has been undercut by a political promise made four and a half decades ago with unforeseen economic repercussions.

In the 1960s, when dialysis started gaining traction among doctors treating chronic kidney failure, most patients couldn’t afford its $30,000 price tag—and it wasn’t covered by insurance. This led to treatment rationing and the arrival of death panels to the American consciousness. In 1972, Richard Nixon signed a government mandate to pay for dialysis for anyone who needed it. At the time, the moral cost of failing to provide lifesaving care was deemed greater than the financial setback of doing so.

But the government accountants, unable to see the country’s coming obesity epidemic and all its attendant health problems, greatly underestimated the future need of the nation. In the decades since, the number of patients requiring dialysis has increased fiftyfold. Today the federal government spends as much on treating kidney disease—nearly $31 billion per year—as it does on the entire annual budget for the National Institutes of Health. The NIH devotes $574 million of its funding to kidney disease research to improve therapies and discover cures. It represents just 1.7 percent of the annual total cost of care for the condition.

But Shuvo Roy, a professor in the School of Pharmacy at UC San Francisco, didn’t know any of this back in the late 1990s when he was studying how to apply his electrical engineering chops to medical devices. Fresh off his PhD and starting a new job at the Cleveland Clinic, Roy was a hammer looking for interesting problems to solve. Cardiology and neurosurgery seemed like exciting, well-funded places to do that. So he started working on cardiac ultrasound. But one day, a few months in, an internal medicine resident at nearby Case Western Reserve University named William Fissell came up to Roy and asked: “Have you ever thought about working on the kidney?”

Roy hadn’t. But the more Fissell told him about how stagnant the field of kidney research had been, how ripe dialysis was for a technological overhaul, the more interested he got. And as he familiarized himself with the machines and the engineering behind them, Roy began to realize the extent of dialysis’ limitations—and the potential for innovation.

Limitations like the pore-size problem. Dialysis does a decent job cleansing blood of waste products, but it also filters out good stuff: salts, sugars, amino acids. Blame the polymer manufacturing process, which can’t replicate the 7-nanometer precision of nephrons—the kidney’s natural filters. Making dialysis membranes involves a process called extrusion, which yields a distribution of pore sizes—most are about 7nm but you also get some portion that are much smaller, some that are much larger, and everything in between. This is a problem because that means some of the bad stuff (like urea and excess salts) can sneak through and some of the good stuff (necessary blood sugars and amino acids) gets trapped. Seven nanometers is the size of albumin—a critical protein that keeps fluid from leaking out of blood vessels, nourishes tissues, and transports hormones, vitamins, drugs, and substances like calcium throughout the body. Taking too much of it out of the bloodstream would be a bad thing. And when it comes to the kidney’s other natural functions, like secreting hormones that regulate blood pressure, dialysis can’t do them at all. Only living cells can.

“We were talking about making a better Bandaid,” Roy says. But as he and Fissell looked around them at the advances being made in live tissue engineering, they started thinking beyond a better, smaller, faster filter. “We thought, if people are growing ears on the backs of mice, why can’t we grow a kidney?”
It turned out, someone had already tried. Sort of.

Back in 1997 when Fissell and Roy were finishing up their advanced training at Case Western, a nephrologist named David Humes at the University of Michigan began working to isolate a particular kind of kidney cell found on the backend of the nephron. Humes figured out how to extract them from cadaver kidneys not suitable for transplant and grow them in his lab. Then he took those cells and coated the inside of hollow fibre-membrane filled tubes similar to the filter cartridge on modern dialysis machines. He had invented an artificial kidney that could live outside the human body on a continuous flow of blood from the patient and do more than just filter.

The results were incredibly encouraging. In clinical trials at the University of Michigan Hospital, it improved the mortality rates for ICU patients with acute renal failure by half. There was just one problem. To work, the patient had to be permanently hooked up to half a hospital room’s worth of tubes and pumps.
The first time Roy saw Humes’ set-up, he immediately recognized its promise—and its limitations. Fissell had convinced him to drive from Cleveland to Ann Arbor in the middle of a snowstorm to check it out. The trip convinced them that the technology worked. It was just way too cumbersome for anyone to actually use it.

The bioartificial kidney is a compact, surgically implanted, free-standing device to treat end stage renal disease (ESRD). It performs the vast majority of the biological functions of the natural kidney.

In 2000, Fissell joined Humes to do his nephrology fellowship at Michigan. Roy stayed at the Cleveland Clinic to work on cardiac medical devices. But for the next three years, nearly every Thursday afternoon Fissell hopped in his car and drove three hours east on I-90 to spend long weekends in Roy’s lab tackling a quintessentially 21st century engineering problem: miniaturization. They had no money, and no employees. But they were able to ride the wave of advancements in silicon manufacturing that was shrinking screens and battery packs across the electronics industry. “Silicon is the most perfected man-made material on Earth,” Roy says from the entrance to the vacuum-sealed clean room at UCSF, where his grad students produce the filters. If they want to make a slit that’s 7 nanometers wide, they can do that with silicon every time. It has a less than one percent variation rate.

The silicon filters had another advantage, too. Because Roy and Fissell wanted to create a small implantable device, they needed a way to make sure there wasn’t an immune response—similar to transplant rejection. Stacks of silicon filters could act as a screen to keep the body’s immune cells physically separated from Humes’ kidney cells which would be embedded in a microscopic scaffold on the other side. The only thing getting through to them would be the salt and waste-filled water, which the cells would further concentrate into urine and route to the bladder.
By 2007 the three researchers had made enough progress to apply for and receive a 3-year $3 million grant from the NIH to prove the concept of their implantable bioartificial kidney in an animal model. On the line was a second phase of funding, this time for $15 million, enough to take the project through human clinical trials. Roy moved out west to UCSF to be closer to the semiconductor manufacturing expertise in the Bay Area. Fissell worked on the project for a few more years at the Cleveland Clinic before being recruited to Vanderbilt while Humes stayed at the University of Michigan to keep working with his cells. But they didn’t make the cut. And without money, the research began to stall.

By then though, their kidney project had taken on a following of its own. Patients from all over the world wanted to see it succeed. And over the next few years they began donating to the project—some sent in five dollar bills, others signed checks for a million dollars. One six-year-old girl from upstate New York whose brother is on dialysis convinced her mother to let her hold a roadside garden vegetable sale and send in the proceeds. The universities chipped in too, and the scientists started to make more progress. They used 3D printing to test new prototypes and computer models of hydraulic flow to optimize how all the parts would fit together. They began collaborating with the surgeons in their medical schools to figure out the best procedure for implanting the devices. By 2015 the NIH was interested again. They signed on to another $6 million over the next four years. And then the FDA got interested.

That fall the agency selected the Kidney Project to participate in a new expedited regulatory approval plan intended to get medical innovations to patients faster. While Roy and Fissell have continued to tweak their device, helped along by weekly shipments of cryogenically frozen cells from Humes’ lab, FDA officials have shepherded them through two years of preclinical testing, most of which has been done in pigs, and shown good results. In April, they sent 20 agency scientists out to California to advise on their next step: moving into humans.
The plan is to start small—maybe ten patients tops—to test the safety of the silicon filter’s materials. Clotting is the biggest concern, so they’ll surgically implant the device in each participant’s abdomen for a month to make sure that doesn’t happen. If that goes well they will do a follow-up study to make sure it actually filters blood in humans the way it’s supposed to. Only then can they combine the filter with the bioreactor portion of the device, aka Humes’ renal cells, to test the full capacity of the artificial kidney.

The scientists expect to arrive at this final stage of clinical trials, and regulatory approval, by 2020. That may sound fast, but one thing they’ve already got a jump on is patient recruiting. Nearly 9,000 of them have already signed up to the project’s waitlist, ready to be contacted when clinical trials get the green light.

These patients are willing to accept the risk of pioneering a third option, besides transplants, which are too expensive and too hard to get for most people, and the drudgery of dialysis. Joseph Vassalotti, a nephrologist in Manhattan and the Chief Medical Officer for the National Kidney Foundation says “the more choices patients have the better,” even though he’s skeptical the device will become a reality within the next few years. An implantable kidney would dramatically improve their quality of life and be a welcome innovation after so many years of treatment status quo. “During World War II we didn’t think dialysis would be possible,” Vassalotti says. “Now half a million Americans are being treated with it. It’s amazing the progress just a few decades make.”

1Correction: 12:50pm ET The Kidney Project is now slated to begin clinical trials in early 2018. A previous version of this article incorrectly stated they would take place later this year. Changes have also been made to correctly identify the size and timing of grants to the Kidney Project.

NEW TREATMENT TIME TO BEGIN

After being on dialysis on mostly afternoons for nearly 10 months, a schedule change will find me moving into an early-morning slot starting shortly after 7 o’clock on three days each week.

Going to work at what I term as my new part-time job, the early time is nothing new. As an army cook while serving in the U.S. Army Reserves, there were many dark mornings where a 12-hour shift would begin as early as 4 o’clock. The mission would be to crack enough eggs in preparing to handle 300 to 500 hungry soldiers lining up to consume a menu of eggs cooked to order, trays upon trays of bacon, stacks of hotcakes, sometimes oatmeal or grits and biscuits or toast. Preparation had to be completed in about 90 minutes, with all the troops being fed generally within a one-hour feeding window. The army does like to get its numbers at their workplaces rather early. And as the bromide is stated: “An army does travel on its stomach.”

While working at various newspapers over a 50-year period, some stops required rather early hours. While at the Indianapolis News in the 1980s, the starting time was 3:30, with a half-dozen edition deadlines to be met one after another methodically by noon. At the Belvidere Daily Republican in Northern Illinois, the day would begin at 4 o’clock in the morning to put together the editorial page, then a quick trip home to clean up for the day, before returning to the office by 7 a.m.

I am looking forward to the new treatment time. My wife, Maureen, may differ with the time change, since she will need to rise earlier than usual to transport me to the treatment center about 15 minutes away. We are still searching for a way to get me home, with treatments to be completed generally no later than 11:30. It’s a long walk home — about six miles. Since Maureen is still working full time, her schedule does not always allow her to be available for transportation needs. Maybe I should consider one of those electric and driver-less Tesla vehicles; I don’t think Medicare would take care of that, though.

One benefit that might arise from the treatment time change, though, is it will provide me with consistent hours to promote my new book (Dialing in on DI-AL-Y-SIS) at least half a day on the three dialysis treatment days.

CAVORTING WITH THE AISLES OF AUTHORS

There I was last Saturday (December 2) looking in the bathroom mirror early in the morning, trying to decide whether to attend the popular Holiday Author Fair at the Eugene & Marilyn Glick Indiana History Center on West Ohio Street. As a retired newspaper vagabond and late-in-life book writer with a recent book release of his own (Dialing in on DI-AL-Y-SIS), I was curious to see what real authors look like.

Staged in the Indiana Historical Society Library & Archive, what was promised as “a fun-filled day of mixing, mingling and book signing” was up to its hype. There were dozens of bona fide authors sitting at tables offering their books for public consumption, and some who have been doing so at this annual holiday event for more than a decade.

There were many prominent authors among those whose literary work were displayed at the Holiday Author Fair.

For example, former Indiana legislator Michael B. Murphy caught my eye. Situated in the History book section, Murphy was touting a book titled The Kimberlins Go to War: A Union Family in Copperhead Country. His story centers on a family that sent 33 fathers and sons, brothers and cousins, to fight for the Union during the Civil War. Ten family members were killed, wounded, or died of battlefield disease, a 30-percent casualty rate that is unmatched in recorded Scott County history.

Also in the History section was a likely recognizable name for many. Andrea Neal was offering Road Trip: A Pocket History of Indiana. Neal is a U.S. History and English teacher and also serves as an adjunct scholar and columnist with the Indiana Policy Review Foundation. Until 2003 she was a journalist, most recently at the Indianapolis Star, where she served as reporter, assistant city editor, editorial writer, and editorial page editor.

Abe Aamidor, another former journalist (at The Indianapolis News), was found in the Sports books section. He may have had one of the longer titles of the day — Chuck Taylor, All Star: The True Story of the Man behind the Most Famous Athletic Shoe in History.

One interesting chat was with H.W. Kondras, a Terre Haute woman who was found in the Nonfiction section where her primary presentation was titled Indiana Crosswords, 3rd Edition. But what really caught my attention was another of her books on display — Detroit Red Wings: Hockeytown USA Trivia.

Back in the day of black-and-white television (about 65 years ago), when I was an elementary student, the National Hockey League experimented by bringing its brand for viewing to Central Kansas, where I was born and raised. A screen promo was aired between periods that offered information. I responded and was surprised and pleased that the six-team NHL sent me a rule book and black-and-white player cards of every player on all the teams. The teams back then included the Boston Bruins, Chicago Blackhawks, Detroit Red Wings and the New York Rangers in the United States and two from north of the border, the Montreal Canadiens and the Toronto Maple Leafs. Detroit became my favorite team, and the Red Wings’ goalie Terry Sawchuk was my favorite player.

Another quite interesting Nonfiction display belonged to photographers/authors Lee Mandrell and DeeDee Niederhouse-Mandrell and two of their books, Indiana Across the Land and Great Smoky Mountains. Their work is described as breathtaking, with pictures that take those thumbing through the books to many spectacular sites off the beaten path that are both well-known and rarely glimpsed.

DeeDee’s parents, Charlene and Jim Niederhouse, and I visit usually three times a week; Charlene and I are both dialysis patients. I was introduced to DeeDee one morning in the lobby of the treatment center.

Also in view in the Sports section was the work titled Reborn: The Pacers and the Return of Pro Basketball to Indianapolis. Author Mark Montieth was unable to attend the fair, but seeing his books on a table reminded me of one of his writing efforts that I found particularly compelling. Being an end stage kidney disease patient, I was moved by his personal account of battling cancer, and doing so by opting for treatment other than what is customarily prescribed in the United States. His cancer story is available online at www.markmontieth.com. It’s a very worthwhile read.

And so worthwhile was a couple of hours spent at the Holiday Author Fair, where I discovered there is no stereotype for what these book-writing wizards look like. That is sure a great relief for what I saw in the mirror at the start of the day.

But for the disGrace of this Bruce Almighty

It may be dangerous for an old man, a retired journalist like myself who is tethered on a dialysis machine three days a week totaling around a dozen hours, to have plenty of available time to conjure up such nonsense as the poetic effort that follows. Since I am also a facebook neophyte, I am offering this October writing that may be of interest to baseball followers, and those who viewed the 2003 movie Bruce Almighty that starred Jim Carrey, Jennifer Anniston, Morgan Fairchild and others.

*See below the names of Major League Baseball players listed on 2017 season rosters who are utilized in the following poem. You will note the verses carry an 11-11-7-7-11-11 rhythmic flow in somewhat Shakespearean fashion. Don’t miss the subtlety of the title and the content.

By Bernie Gilmer, October, 2017
(With apologies to Bill S. himself)

Looking for a Street where they could raise some Cain,
These mischievous youngsters out in the light rain.
Weaving right up a steep Hill,
With each one popping a Pill.
Two Brothers, one Walker a heavy Smoker,
Three were country Hicks, another a joker.

One suggested they buy some mighty Good-rum;
One Wheeler-dealer said he would get them some.
Instead, he bought a Gallo jug.
Bummer! Yelled the littlest thug,
And adding: Great Scott, man, must have been on Sale,
Should’a brought some White wine iced down in a pail.

As it moved toward toMorrow, chirping was heard,
Led by a Jay, a Martin, and a big Bird
Known as a strutting Peacock.
A Covey joined courthouse clock.
Also roaming was one lone County Sher(r)iff,
Who found the Hardy teens and got into a tiff.

One rascal ran and hid behind a large Bush,
One in a bed of Flowers trying to hush.
The cop from his holster he Drew,
While down the tracks came choo-Choo,
Giving an escape hatch for those from the Hood,
As if the curfew Bell wasn’t understood.

But leave it up to the long arm of the Law,
To patrol the town in a shiny rickShaw
Owned by the Danish Baker,
The tall German Shoemaker,
A stout Gray-haired Carpenter eager-beaver
And a Green-eyed Albu(r)querque Weaver.

Well, the determined ‘Barney Fife’ failed to budge,
Rounded up the lads for a fill-in court Judge.
Would he rule ‘Minor offense’?
Or Hand out something quite tense?
One ladies-man brat showed he’s a real Winker,
Another’s Story proved he was a stinker.

Would the man with the gavel grant some Leeway,
Or come down hard with a hefty Price to pay?
You don’t need to break Morse code,
Wade in on pie a-la-mode,
Find a Phillips screwdriver or Allen wrench.
Riddle will be solved by the man on the bench.

Over a Span of time, we all will get to hear
Whether the ruling protects those who wreak fear,
like football’s soft Brady Rule,
sends these rowdies back to school.
Oh, and it makes each appear like a Free-man,
With Morton salt in wounds of those in Free-lan(d).

Surely, this edict was made by a Dull mind,
Donning judicial robe as a sub-in kind.
Offering his sixPence worth,
Which May be his last henceforth.
Gee, while his ruling was viewed as unsightly,
Could be the disGrace of this Bruce Almighty?

*Players & their teams.

Al Alburquerque, P, Chicago White Sox
Brandon Allen, 1B, Cincinnati Reds
Cody Allen, P, Cleveland Indians
Greg Allen, OF, Cleveland Indians

Dylan Baker, P, Cleveland Indians
Jeff Baker, 1B, Miami Marlins
John Baker, C, Chicago Cubs
Scott Baker, P, Los Angeles Dodgers
Chad Bell, P, Detroit Tigers
Heath Bell, P, Washington Nationals
Josh Bell, IF, Los Angeles Dodgers
Josh Bell, 1B, Pittsburgh Pirates
Trevor Bell, P, Cincinnati Reds
Greg Bird, 1B, New York Yankees
Michael Brady, OF, Oakland Athletics
Rex Brothers, P, Atlanta Braves
Jay Bruce, OF, Cleveland Indians
Aaron Bummer, P, Chicago White Sox
Matt Bush, P, Texas Rangers

Lorenzo Cain, OF, Kansas City Royals
Matt Cain, P, San Francisco Giants
Chris Carpenter, P, Boston Red Sox
David Carpenter, P, Atlanta Braves
David Carpenter, P, Tampa Bay Rays
Matt Carpenter, 1B, St. Louis Cardinals
Shin-Soo Choo, OF, Texas Rangers
Dylan Covey, P, Chicago White Sox

Tyler Danish, P, Chicago White Sox
Stephen Drew, IF, Washington Nationals
Ryan Dull, P, Oakland Athletics

Tyler Flowers, C, Atlanta Braves
Freddie Freeman, 1B, Atlanta Braves
Mike Freeman, IF, Chicago Cubs
Sam Freeman, P, Atlanta Braves
Kyle Freeland, P, Colorado Rockies

Joey Gallo, IF, Texas Rangers
Dillon Gee, P, Minnesota Twins
Domingo German, P, New York Yankees
Niko Goodrum, OF, Minnesota Twins
Matt Grace, P, Washington Nationals
Jon Gray, P, Colorado Rockies
Sonny Gray, P, New York Yankees
Chad Green, P, New York Yankees
Grant Green, IF, Washington Nationals

Brad Hand, P, San Diego Padres
Donovan Hand, P, Cincinnati Reds
J.J. Hardy, IF, Baltimore Orioles
Aaron Hicks, New York Yankees
Brandon Hicks, IF, San Francisco, Giants
John Hicks, C, Detroit Tigers
Aaron Hill, OF, San Francisco Giants
Koyie Hill, C, Philidelphia Phillies
Rich Hill, P, Los Angeles Dodgers
Shawn Hill, P, Toronto Blue Jays
Taylor Hill, P, Washington Nationals
Destin Hood, OF, Miami Marlins

Jon Jay, OF, Chicago Cubs
Aaron Judge, OF, New York Yankees

Derek Law, P, San Francisco Giants
C.C. Lee, P, Cleveland Indians
Chris Lee, P, Baltimore Orioles
Dae-Ho Lee, 1B, Seattle Mariners
Zach Lee, San Diego Padres

Chris Martin, P, New York Yankees
Cody Martin, P, Seattle Mariners
Ethan Martin, P, Philadelphia Phillies
J.D. Martin, P, Chicago White Sox
Kyle Martin, P, Boston Red Sox
Leonys Martin, OF, Chicago Cubs
Rafael Martin, P, Washington Nationals
Russell Martin, C, Toronto Blue Jays
Jacob May, OF, Chicago White Sox
Trevor May, P, Minnesota Twins
Mike Minor, P, Kansas City Royals
Brandon Morrow, P, Los Angeles Dodgers
Michael Morse, 1B, San Francisco Giants
Charlie Morton, P, Houston Astros

Seung Hwan Oh, P, St. Louis Cardinals

Brad Peacock, P, Houston Astros
Hunter Pence, OF, San Francisco Giants
Brandon Phillips, IF, Los Angeles Angels
Brett Phillips, OF, Milwaukee Brewers
Zach Phillips, P, Pittsburgh Pirates
Tyler Pill, P, New York Mets
Bryan Price, Cleveland Indians
David Price, Boston Red Sox

J.T. Riddle, IF, Miami Marlins

Chris Sale, P, Boston Red Sox
Luke Scott, DH, Tampa Bay Rays
Robby Scott, P, Boston Red Sox
Bryan Shaw, P, Cleveland Indians
Travis Shaw, IF, Milwaukee Brewers
Tanner Sherriff, P, St. Louis Cardinals
Matt Shoemaker, P, Los Angeles, Angels
Josh Smoker, P, New York Mets
Denard Span, OF, San Francisco Giants
Trevor Story, IF, Colorado Rockies
Huston Street, P, Los Angeles Angels

Tyler Wade, IF, New York Yankees
Christian Walker, 1B, Arizona Diamondbacks
Neil Walker, IF, Milwaukee Brewers
Taijujan Walker, P, Arizona Diamondbacks

Jered Weaver, P, San Diego Padres
Luke Weaver, P, St. Louis Cardinals
Jason Wheeler, P, Los Angeles Dodgers
Ryan Wheeler, IF, Los Angeles Angels
Zack Wheeler, P, New York Mets
Alex White, P, Houston Astros
Tyler White, P, Houston Astros
Jesse Winker, OF, Cincinnati Reds

Chris Young, OF, Boston Red Sox
Chris Young, P, Kansas City Royals
Delman Young, OF, Baltimore Orioles
Delwyn Young, OF, Chicago White Sox
Eric Young, OF, Los Angeles Angels

NOTE: All 30 Major League Baseball teams are included (by 64 last names representing 115 players) somewhere in the poem.